A phase III, randomized, placebo-controlled trial in 171 patients with advanced-stage pancreatic neuroendocrine tumors demonstrated a significant improvement in progression-free survival with sunitinib treatment. We discuss the results of this trial in the context of other studies that have assessed treatment of pancreatic neuroendocrine tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).
McCollum, A. D. et al. Lack of efficacy of streptozotocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am. J. Clin. Oncol. 27, 485–488 (2004).
Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734–745 (2007).
Kulke, M. H. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403–3410 (2008).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
Shen, H. C. et al. Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 69, 1858–1866 (2009).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Alsamarai, S., Libutti, S. K. & Saif, M. W. Updates in pancreatic neuroendocrine carcinoma. Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4–8, 2010. JOP 11, 336–340 (2010).
Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. K. Libutti has received a travel grant from Novartis. A. M. Spiegel declares no competing interests.
Rights and permissions
About this article
Cite this article
Spiegel, A., Libutti, S. Good news for advanced-stage pancreatic neuroendocrine tumors. Nat Rev Clin Oncol 8, 258–259 (2011). https://doi.org/10.1038/nrclinonc.2011.50
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.50
This article is cited by
-
Blockade of IGF-1R—not effective in neuroendocrine tumours
Nature Reviews Endocrinology (2013)